arrow
M

Michaël Loschi

department of hematology
H指数:23
被引数:2,957

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

大B细胞淋巴瘤CAR T细胞疗法后的应答动力学:DESCAR-T登记研究中的LYSA研究

2026-08-210
PRE
Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC

HLA匹配造血干细胞移植中干细胞来源对首次完全缓解急性淋巴细胞白血病的影响:GRAALL和SFGM-TC的研究

2026-04-160
PRE
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee

定义异基因造血细胞移植后骨髓增生异常/骨髓增生性肿瘤的缓解和复发,并优化移植结果:EBMT实践协调与指南委员会的建议

2026-04-010
PRE
Acetyl-CoA carboxylase 1 inhibition increases Treg metabolism and graft-versus-host disease treatment efficacy via mitochondrial fusion

McDonald-Hyman C,Aguilar EG,Compeer EB,Zaiken MC,Rhee SY,Mohamed FA,等。乙酰辅酶A羧化酶1抑制通过线粒体融合增加Treg代谢并提高移植物抗宿主病治疗效率。临床研究杂志。(2025) 135:e182480。doi: 10.1172/JCI182480。

2025-12-011
OA
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry

CAR T细胞疗法后侵袭性B细胞淋巴瘤的晚期复发:一项来自DESCAR-T登记研究的LYSA研究

2025-10-240
OAAI
Transplantation in lower risk MDS patients: a prospective phase 2 trial based on donor availability

低风险MDS患者的移植治疗:一项基于供者可及性的前瞻性II期试验

2025-10-100
OAAI
Myeloid neoplasms risks for germline DDX41 pathogenic variants carriers

携带胚系DDX41致病性变异的髓系肿瘤风险

2025-10-030
PRE
Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC

硫替派-白消安-氟达拉滨与氯法拉滨为基础的预处理方案在异基因移植联合移植后环磷酰胺治疗髓系恶性肿瘤患者中的比较:一项来自SFGM-TC的回顾性研究

2025-09-150
PRE
Allogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies

同种异基因造血干细胞移植在种系DDX41突变伴髓系恶性肿瘤患者中的应用

2025-09-110
OAAI
Real World Experience of Azacitidine plus Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial

真实世界中阿扎胞苷联合维奈克拉治疗急性髓系白血病严格遵循临床试验管理指南的经验

2025-09-010
PRE
Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)

异基因造血干细胞移植治疗老年急性淋巴细胞白血病患者:一项来自Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)的登记研究

2025-05-060
PRE
Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial

口服混合粪菌疗法在强化化疗后重建肠道微生物组:CIMON 1b 期试验

2025-04-100
OA
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry

复发或难治性原发纵隔B细胞淋巴瘤患者接受抗CD19 CAR-T细胞治疗的结局:CARTHYM,一项来自法国国家DESCAR-T登记研究的报告

2025-02-182
OAAI
Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK-Positive Anaplastic Large-Cell Lymphoma: A Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

异基因干细胞移植治疗复发/难治性ALK阳性间变性大细胞淋巴瘤:一项来自Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)的研究

BLOOD
IF23.1
2024-11-050
PRE
Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

细胞因子调节与接受Nuvisertib(TP-3654)治疗骨髓纤维化患者的症状改善显著相关,Nuvisertib是一种在研的选择性PIM1激酶抑制剂。

BLOOD
IF23.1
2024-11-050
PRE
Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry
2024-10-230
OAAI